Connor, Clark & Lunn Investment Management (CC&L)’s Passage Bio PASG Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,145	Closed	-$79.4K	–	1445
2023 Q1	$79.4K	Buy	4,145 +29	+0.7%	+$786	﹤0.01%	1171
2022 Q4	$114K	Sell	4,116 -276	-6%	-$6.96K	﹤0.01%	1102
2022 Q3	$110K	Buy	4,392 +2,376	+118%	+$93.6K	﹤0.01%	1035
2022 Q2	$95K	Sell	2,016 -299	-13%	-$14K	﹤0.01%	982
2022 Q1	$144K	Buy	2,315 +1,149	+99%	+$94.7K	﹤0.01%	962
2021 Q4	$148K	Buy	+1,166	New	+$190K	﹤0.01%	1008

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PASG Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Passage Bio (PASG) in Q2 2023, closing a stake of 4,145 shares — an estimated $79.4K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PASG in Q4 2021 and held it in 6 quarters. The position peaked at $148K in Q4 2021. 54 funds tracked by Wall St. Rank hold PASG as of Q2 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Passage Bio position as of Q2 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 4,145 Passage Bio shares in Q2 2023, an estimated $79.4K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Passage Bio in Q4 2021 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Passage Bio position peaked at $148K in Q4 2021.
54 funds tracked by Wall St. Rank held Passage Bio as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.